Visby Medical is redefining the future of women’s health with a groundbreaking milestone: regulatory clearance for the first-ever at-home, instrument-free PCR test for sexually transmitted infections (STIs). This breakthrough brings clinical-grade diagnostics directly into the hands of patients—eliminating barriers, reducing stigma, and making timely care more accessible than ever.

This innovation reflects Visby Medical’s commitment to empowering individuals with fast, accurate, lab-quality results from the comfort of home. By delivering high-performance PCR technology in a simple, handheld format, Visby continues to lead the charge in transforming diagnostics and expanding access to essential sexual health tools.

At 1809 Capital, we are proud to support founders and companies like Visby who push the boundaries of what’s possible in healthcare. Their work is a powerful example of how thoughtful engineering, patient-centered design, and scientific rigor can create meaningful change—locally and globally.